Ureteral reconstruction and Urinary conduits

ESGO eAcademy, Luis M. Chiva, 209153

Bowel surgery 

ESGO eAcademy, David Cibula, 209152

Bowel preparation

ESGO eAcademy, Dimitrios Haidopoulos, 209151

Video Assisted Thoracoscopic Surgery (VATS)

ESGO eAcademy, Murat Gultekin, 209150

Stomach mobilization - resection - placement of J-tube

ESGO eAcademy, Jalid Sehouli, 209149

Dissection of Porta Hepatis, Celiac Trunk and Techniques for Cholecystectomy

ESGO eAcademy, Denis Querleu, 209148

Splenectomy and Distal Pancreatectomy

ESGO eAcademy, David Cibula, 209147

Diaphragm stripping - resection - repair

ESGO eAcademy, Anna Fagoti, 209146

Liver Mobilization & Cardio-Phrenic LND

ESGO eAcademy, Luis M. Chiva, 209145

Morbidity and postoperatieve outcome

ESGO eAcademy, Jalid Sehouli, 209144

Nutrition

ESGO eAcademy, Philippe Morice, 209143

Modified posterior exenteration and Excision of the pouch of Douglas sparing the rectum

ESGO eAcademy, Philippe Morice, 209141

Pelvic and Paarotic llymphadenectomy

ESGO eAcademy, Denis Querleu, 209140

Evaluation of the extension of the disease

ESGO eAcademy, Anna Fagoti, 209139

Science of tissue management - energy and hemostats, stapplers, ednocutters

ESGO eAcademy, Dimitrios Haidopoulos, 209138

The aim of cytoreduction in ovarian cancer surgery

ESGO eAcademy, Murat Gultekin, 209137

CURRENT AND FUTURE DIRECTIONS FOR GRANULOSA CELL TUMOUR MANAGEMENT

ESGO eAcademy, Isabelle Ray-Coquard, 202840

WHAT IS THE STATE-OF-THE-ART FOR OVARIAN GERM CELL TUMOURS?

ESGO eAcademy, Jalid Sehouli, 202839

HEREDITARY GYNAECOLOGICAL CANCERS: PREVENTION AND ROLE OF PROPHYLACTIC SURGERIES

ESGO eAcademy, Ranjit Manchanda, 202843

HOW CAN WE ELIMINATE DEATHS IN HIGH RISK GTN?

ESGO eAcademy, Michael Seckl, 202838

STATE OF ART IN SCREENING OF GYNAECOLOGICAL CANCERS

ESGO eAcademy, Murat Gultekin, 202842

RECENT DEVELOPMENTS IN GTD AND MOLAR PREGNANCIES

ESGO eAcademy, Leon Massuger, 202837

THE IMPACT OF HEALTHY LIFE STYLE AND OBESITY ON PREVENTION OF GYNAECOLOGICAL CANCERS

ESGO eAcademy, Maria Kyrgiou, 202841

LAPAROSCOPIC VERSUS OPEN TREATMENT OF ENDOMETRIAL CANCER IN ELDERLY WOMEN

ESGO eAcademy, Ignacio Zapardiel, 202833

PREDICTIVE MARKERS IN CERVICAL CANCER

ESGO eAcademy, Cornelis D de Kroon, 203136

ELDERLY PATIENTS UNDERGOING SURGERY FOR OVARIAN OR CERVICAL CANCER: PERI-OPERATIVE ASSESSMENT AND SURGICAL CHOICES

ESGO eAcademy, Dina Kurdiani, 202832

PREDICTIVE MARKERS IN OVARIAN CARCINOMA

ESGO eAcademy, Alexandra Leary, 202835

FRAILTY EVALUATION AND MEDICAL TREATMENT OF ELDERLY POPULATION WITH GYNAECOLOGICAL MALIGNANCIES

ESGO eAcademy, Annamaria Ferrero, 202831

PREDICTIVE MARKERS IN ENDOMETRIAL CARCINOMA

ESGO eAcademy, Xavier Matias-Guiu, 202834

SUPPORTIVE CARE FOR WOMEN WITH GYNAECOLOGIC CANCER RECEIVING EXTERNAL BEAM RADIOTHERAPY AND BRACHYTHERAPY

ESGO eAcademy, Alina Sturdza, 202830

SUPPORTIVE CARE IN GYNECOLOGIC CANCER PATIENTS RECEIVING MEDICAL TREATMENT

ESGO eAcademy, Jørn Herrstedt, 202829

PERIOPERATIVE SUPPORTIVE CARE IN GYNECOLOGIC CANCER PATIENTS

ESGO eAcademy, Felix Hilpert, 202828

CERVICAL ADENOCARCINOMA IB1 AFTER RADICAL HYSTERECTOMY, POSITIVE LYMPHNODES - EVALUATION OF PERIAORTIC NODES, ADJUVANT THERAPY, MANAGEMENT OF OVARIES

ESGO eAcademy, Sebastien Gouy, 202824

CASE 3: DISTANT METASTASES, ENDOCRINE THERAPY, CHEMOTHERAPY

ESGO eAcademy, Guenter Emons, 202827

PLATINUM ELIGIBLE RECURRENT OVARIAN CANCER

ESGO eAcademy, Cristiana Sessa, 202820

CERVICAL CANCER IB1, 2CM TUMOR DIAMETER: SLN BIOPSY, MANAGEMENT IN REGARD TO ABSENCE/PRESENCE OF METASTATIC DISEASE

ESGO eAcademy, Alexander W. Reinthaller, 202823

CASE 2: ADVANCED, METASTATIC, TREATMENT WITH RADIOTHERAPY AND CHEMOTHERAPY

ESGO eAcademy, Melanie Powell, 202826

RECURRENT OVARIAN CANCER - ROLE OF SURGERY

ESGO eAcademy, Philipp Harter, 202819

SURGICAL MANAGEMENT IN PRIMARY OVARIAN CANCER

ESGO eAcademy, Giovanni Aletti, 202818

CERVICAL CANCER STAGE IB1, 3CM TUMOR DIAMETER: EVALUATION OF LYMPH NODES, RISK FACTORS AND THERAPEUTIC MANAGEMENT

ESGO eAcademy, Remi Nout, 202822

CASE 1: ADVANCED ENDOMETRIAL CANCER, AMENABLE TO SURGICAL RESECTION, ROLE OF NEOADJUVANT CHEMOTHERAPY

ESGO eAcademy, Frederic Amant, 202825

CURRENT CLINICALLY MEANINGFUL ASPECTS IN HEREDITARY UTERINE CANCER INCLUDING LYNCH SYNDROME

ESGO eAcademy, Uzi Beller, 202814

THE IMMUNOTHERAPY STORY

ESGO eAcademy, Lana Kandalaft, 202817

CURRENT CLINICALLY MEANINGFUL ASPECTS AND IMPORTANCE OF GERMLINE AND SOMATIC MUTATIONS IN HEREDITARY OVARIAN CANCER

ESGO eAcademy, Pauline Wimberger, 202813

THE PARP-I STORY

ESGO eAcademy, Andres Poveda, 202816

CURRENT CLINICALLY MEANINGFUL ASPECTS AND IMPORTANCE OF GERMLINE AND SOMATIC MUTATIONS IN HEREDITARY BREAST CANCER

ESGO eAcademy, Jan Lubinski, 202812

SURGICAL TRAILS

ESGO eAcademy, Andreas Du Bois, 202815

Conservative surgery for the treatment of granulosa cell tumors of the ovary: results from the MITO 9 study

ESGO eAcademy, Alice Bergamini, 202926

A COMPARATIVE STUDY OF TWO FOLLOW-UP STRATEGIES FOLLOWING TREATMENT OF ENDOMETRIAL CANCER BETWEEN AN ITALIAN AND A UK CENTRE

ESGO eAcademy, Valentina Ghirardi, 203531

HOW TO ASSESS RESECTABILITY AT PRIMARY SURGERY?

ESGO eAcademy, Anna Fagoti, 202808

WHICH ROLE CAN PATIENT REPORTED OUTCOMES AND QUALITY OF LIFE HAVE IN CLINICAL TRIALS

ESGO eAcademy, Remi Nout, 202811

Prospective Clinical Cohort Study For Efficacy Assessment Of Topical Treatment With Olivoleina On Post-Surgical Scars In Patients Undergoing Radiotherapy For Gyneacologic Cancers

ESGO eAcademy, Jesus Molero Vilchez, 202925

ANGIOGENESIS

ESGO eAcademy, Sandro Pignata, 202807

HOW TO INTEGRATE PATIENT REPORTED OUTCOME TOOLS IN THE EVERYDAY GYNAECOLOGICAL CANCER CLINIC

ESGO eAcademy, Galina Velikova, 202810

BRCA/HRD

ESGO eAcademy, Jonathan A Ledermann, 202806

OVERVIEW OF CURRENT DEVELOPMENTS IN MEASURING AND REPORTING PATIENT REPORTED OUTCOMES AND QUALITY OF LIFE IN GYNAECOLOGICAL CANCER

ESGO eAcademy, Lonneke van de Poll-Franse, 202809

MANAGEMENT OF RECURRENT DISEASE

ESGO eAcademy, Frederic Amant, 202799

CERVICAL CANCER IMMUNOTHERAPY TRIAL

ESGO eAcademy, Hans Nijman, 202804

CONSERVATIVE TREATMENT OF ENDOMETRIAL CANCER IN YOUNG WOMEN

ESGO eAcademy, Dimitrios Haidopoulos, 202798

OVARIAN CANCER IMMUNOTHERAPY TRIALS

ESGO eAcademy, Jonathan A Ledermann, 202803

RADICAL TREATMENT OF ENDOMETRIAL CANCER IN YOUNG WOMEN

ESGO eAcademy, Nicoletta Colombo, 202797

RISK FACTORS AND PATHOGENESIS OF ENDOMETRIAL CANCER IN YOUNG WOMEN

ESGO eAcademy, Vesna Kesic, 202796

PRINCIPLES OF IMMUNOTHERAPY

ESGO eAcademy, Christian Marth, 202801

Prognostic Value Of Lymph Node Ratio And Number Of Positive Inguinal Nodes In Patients With Vulvar Cancer

ESGO eAcademy, Richard Schwameis, 202924

ONCOLOGICAL MANAGEMENT AND PREGNANCY OUTCOMES IN WOMEN DIAGNOSED WITH CANCER DURING PREGNANCY: A 20-YEAR INTERNATIONAL COHORT STUDY OF 1170 PATIENTS

ESGO eAcademy, Frederic Amant, 202790

MECHANISMS OF RESISTANCE IN BRCA MUTATED TUMORS

ESGO eAcademy, Clare Scott, 202793

QUALITY OF LIFE WITH WEEKLY, DOSE-DENSE VERSUS STANDARD CHEMOTHERAPY FOR OVARIAN CANCER IN THE ICON8 STUDY

ESGO eAcademy, Sarah Blagden, 202788

CLINICALLY SIGNIFICANT LONG-TERM MAINTENANCE TREATMENT WITH OLAPARIB IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)

ESGO eAcademy, Charlie Gourley, 202787

CLINICAL DEVELOPMENT OF OTHER NON PARP TARGETED THERAPIES

ESGO eAcademy, Cristiana Sessa, 202792

HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) FOR OVARIAN CANCER

ESGO eAcademy, Willemien J. Van Driel, 202786

ARIEL3: PHASE 3, RANDOMISED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA (OC)

ESGO eAcademy, Jonathan A Ledermann, 202785

UPDATE ON THE CLINICAL DEVELOPMENT OF PARP INHIBITORS

ESGO eAcademy, Iain McNeish, 202791

CLINICAL TRIALS IN PLATINUM-RESISTANT DISEASE

ESGO eAcademy, Mansoor Mirza, 202781

Vulvar Cancer In Ireland: Analysis Of The Irish National Cancer Registry Over A 20 Year Period

ESGO eAcademy, Ann Rowan, 203117

STRATEGIES FOR OVERCOMING RESISTANCE TO CHEMOTHERAPY

ESGO eAcademy, Sandro Pignata, 202780

PLATINUM-RESISTANT DISEASE: CURRENT STATUS

ESGO eAcademy, Nicole Concin, 202779

RANKL -BONES, SEX, AND BREAST CANCER

ESGO eAcademy, Josef Penninger, 202794

WHY ARE WE FAILING TO CURE OVARIAN CANCER?"

ESGO eAcademy, Christian Marth, 202795

GENERAL IMPLEMENTATION OF IGABT (TRAINING/ MEANS/HEALTH ECONOMICS/RESOURCE LIMITATIONS)

ESGO eAcademy, Christine Haie-Meder, 202775

WHEN, WHY AND HOW TO TEST MISMATCH REPAIR DEFICIENCY IN ENDOMETRIAL CANCER

ESGO eAcademy, Tjalling Bosse, 202778

IMAGE-GUIDED ADAPTIVE BRACHYTHERAPY VERSUS IMRT/STEREOTACTIC RADIOTHERAPY

ESGO eAcademy, Akila Viswanathan, 202774

WHEN, WHY AND HOW TO TEST FOR L1CAM AND P53 EXPRESSION IN ENDOMETRIAL CANCER

ESGO eAcademy, Alain G. Zeimet, 202777

CURRENT STATUS OF IMAGE-GUIDED BRACHYTHERAPY : ONCOLOGICAL RESULTS AND COMPLICATIONS

ESGO eAcademy, Jacob Lindegaard, 202773

WHEN, WHY AND HOW TO TEST POLE MUTATIONAL STATUS IN ENDOMETRIAL CANCER

ESGO eAcademy, David Church, 202776

Interval Between  Cytoreductive Surgery And Adjuvant Chemotherapy Is Associated With Overall Survival In  Patients With Advanced Ovarian Cancer

ESGO eAcademy, Maite Timmermans, 202923

Outcomes Of Robotic Radical Hysterectomy For Cervical Cancer In Comparison To Laparotomy ; A Population Based Study In The United States

ESGO eAcademy, Sabrina Piedimonte, 202922

TREATMENT OF ADVANCED DISEASE, INCLUDING MANAGEMENT OF MORBIDITY

ESGO eAcademy, Alexandra Taylor, 202769

IMPACT OF VAGINAL MORBIDITY ON SEXUALITY AFTER DEFINITIVE RADIOCHEMOTHERAPY IN LOCALLY ADVANCED CERVICAL CANCER PATIENTS

ESGO eAcademy, Kathrin Kirchheiner, 202772

ADJUVANT TREATMENT

ESGO eAcademy, Carien Creutzberg, 202768

PHYSICAL CONSEQUENCES OF GYNAECOLOGIC CANCER SURGERY AND THEIR IMPACT ON SEXUAL HEALTH

ESGO eAcademy, Michal Zikan, 202771

DIAGNOSTIC AND SURGICAL MANAGEMENT

ESGO eAcademy, Philippe Morice, 202767

SEXUAL HEALTH IN GYNAECOLOGIC CANCER PATIENTS - PSYCHO-SOCIAL CONSEQUENCES OF DIAGNOSIS AND TREATMENT

ESGO eAcademy, Moniek M ter Kuile, 202770

Cervical Cancer Relapse Rates In Patients With Para-Aortic Negitive PET Scans:A Five-Year Analysis In An Irish Gynaeoncology Centre

ESGO eAcademy, Ann Rowan, 202921

Discussion and Closing

ESGO eAcademy, Sandro Pignata, 202898

Patterns Of Lymph Node Metastases In Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study.

ESGO eAcademy, Lucas Minig, 202920

Future therapies

ESGO eAcademy, Kathleen Moore, 202897

Adjuvant management

ESGO eAcademy, Nicoletta Colombo, 202896

Long-Term Efficacy And Immunogenicity Of The 9-Valent Human Papillomavirus Vaccine: Final Analyses Of A Double-Blind, Randomized Clinical Study

ESGO eAcademy, Elmar A. Joura, 202919

Primary debulking strategy

ESGO eAcademy, Sven Mahner, 202895

Front-line Ovarian Cancer: Can we do better?: Welcome and introduction

ESGO eAcademy, Sandro Pignata, 202766